Loading...
Personalis Q1 2025 Earnings Report
Personalis reported a 6% increase in revenue for the first quarter of 2025, driven by growth in pharma tests and services, alongside a net loss of $15.8 million.
Key Takeaways
Personalis, Inc. reported first quarter 2025 revenue of $20.6 million, a 6% increase year-over-year, primarily due to strong growth in pharma tests and services. The company delivered 2,184 total molecular tests, a 52% sequential increase, and reported a net loss of $15.8 million.
Total revenue for Q1 2025 increased by 6% to $20.6 million compared to $19.5 million in Q1 2024.
Pharma tests and services revenue grew by 39% year-over-year to $13.6 million.
The company delivered 2,184 total molecular tests in Q1 2025, a 52% sequential increase from Q4 2024.
Net loss for the quarter was $15.8 million, or $0.18 per share, compared to a net loss of $13.0 million, or $0.26 per share, in Q1 2024.
Revenue by Segment
Forward Guidance
Personalis expects total company revenue for the second quarter of 2025 to be in the range of $19.5 million to $20.5 million, with full-year revenue projected between $80 million and $90 million. The company anticipates continued growth in pharma tests and services revenue.
Positive Outlook
- Total company revenue for Q2 2025 is expected to be in the range of $19.5 million to $20.5 million.
- Revenue from pharma tests and services, and all other customers, is projected to be in the range of $13 million to $14 million for Q2 2025.
- Full-year 2025 total company revenue guidance remains unchanged at $80 million to $90 million.
- Full-year 2025 revenue from pharma tests and services, and all other customers, is expected to be in the range of $62 million to $64 million.
- Gross margin for the full year 2025 is expected to be in the range of 22% to 24%, an increase from prior guidance.
Challenges Ahead
- Revenue from population sequencing and enterprise sales is expected to decrease to approximately $6.5 million for Q2 2025.
- Full-year 2025 revenue from population sequencing and enterprise sales is projected to be lower, in the range of $15 million to $16 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...